Chugai Pharmaceutical is paying PharmaMar €30 million ($31.4 million) upfront for Japanese rights to the latter’s Phase III-stage, marine-derived anticancer drug PM1183 (lurbinectedin). The RNA polymerase II inhibitor is in development for the...
Chugai Pharmaceutical has licensed out worldwide manufacturing, development, and marketing rights to its anticancer candidate PA799 to Menarini Group’s oncology-focused subsidiary Berlin-Chemie Menarini, the companies said today.
SOUTH SAN FRANCISCO (dpa-AFX) - Chugai Pharmaceutical Co., Ltd. said
Genentech Inc., a member of the Roche Group, obtained approval from the U.S.
Food and Drug Administration, for the anti-cancer agent, alectinib hydrochloride
or Alecensa for the...
Oops! Unable to complete your request. Please refresh your browser.
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.
You may also be interested in articles related to Chugai Pharmaceuticals (4519-TO):